IPH Share Price

Open 10.65 Change Price %
High 10.68 1 Day 0.03 0.28
Low 10.59 1 Week -0.09 -0.84
Close 10.65 1 Month -0.27 -2.47
Volume 62328 1 Year -0.23 -2.11
52 Week High 15.83
52 Week Low 9.65
IPH Important Levels
Resistance 2 10.73
Resistance 1 10.70
Pivot 10.64
Support 1 10.60
Support 2 10.57
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
ALDIE 1.24 14.81%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MLPFX 11.55 13.79%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLIML 0.45 -31.82%
FED 10.55 -24.37%
FED 10.55 -24.37%
MLSAT 4.95 -19.12%
ALDOL 12.02 -12.13%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
MLDEX 1.65 -10.33%
ALSOL 5.90 -8.24%
MLERO 0.34 -8.11%
More..

Innate Pharma SA (EPA: IPH)

IPH Technical Analysis 5
As on 23rd Aug 2017 IPH Share Price closed @ 10.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.92 & Strong Sell for SHORT-TERM with Stoploss of 11.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPH Target for August
1st Target up-side 11.17
2nd Target up-side 11.41
3rd Target up-side 11.64
1st Target down-side 10.51
2nd Target down-side 10.27
3rd Target down-side 10.04
IPH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.innate-pharma.com
IPH Address
IPH
117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
IPH Latest News
Turning Attention Towards Innate Pharma SA (IPHYF)'s Technicals   Wall Street Review   - 22nd Aug 17
Issuance by Innate Pharma of 3343748 ordinary shares to Novo Nordisk A/S in ...   GlobeNewswire (press release)   - 13th Jul 17
Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017   GlobeNewswire (press release)   - 23rd May 17
INNATE PHARMA : 2016 reference document made available (in french)   GlobeNewswire (press release)   - 03rd Apr 17
Innate Pharma announces its financial calendar for 2017   GlobeNewswire (press release)   - 04th Jan 17
INNATE PHARMA: Further clinical data for lirilumab and IPH4102 presented at ...   GlobeNewswire (press release)   - 05th Dec 16
Innate Pharma investor conference call on November 14, 2016 to discuss recent ...   GlobeNewswire (press release)   - 10th Nov 16
INNATE PHARMA : Encouraging initial results for IPH4102 presented at the Third ...   GlobeNewswire (press release)   - 26th Oct 16
INNATE PHARMA: Preliminary safety and clinical activity results for IPH4102 to ...   GlobeNewswire (press release)   - 13th Oct 16
Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno ...   GlobeNewswire (press release)   - 24th Apr 15
Interactive Technical Analysis Chart Innate Pharma SA ( IPH EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Innate Pharma SA
IPH Business Profile
Innate Pharma S.A., a biopharmaceutical company, engages in the development of immunotherapy drug candidates for cancer and inflammatory diseases. The company primarily develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors (KIR) in Phase II trials for acute myeloid leukemia and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab respectively; and IPH2201/NN8765, an anti-NKG2A antibody in Phase I clinical trials for the treatment of inflammatory conditions and autoimmune diseases, and in rheumatoid arthritis. The company’s pre-clinical product candidates include IPH41, a cytotoxic mAb that targets KIR3DL2, an inhibitory receptor of NK cells; and IPH33, a blocking mAb targeting TLR3, an inducer of Type I IFN and pro-inflammatory cytokines. It has licensing agreements with Bristol-Myers Squibb for the development of IPH2102; and Novo Nordisk A/S for the development of IPH2201. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.